EP
VRDN icon

Eversept Partners’s Viridian Therapeutics VRDN Stock Holding History

Eversept Partners’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$15.3M Buy
831,142
+117,873
+17% +$1.9M 0.79% 35
2026
Q1 		$14M Sell
713,269
-1,068,966
-60% -$31.7M 0.74% 35
2025
Q4 		$55.5M Sell
1,782,235
-142,071
-7% -$3.9M 2.79% 8
2025
Q3 		$41.5M Buy
1,924,306
+21,767
+1% +$393K 2.86% 10
2025
Q2 		$26.6M Buy
1,902,539
+524,865
+38% +$7.12M 2.45% 10
2025
Q1 		$18.6M Buy
1,377,674
+597,676
+77% +$10.2M 1.89% 18
2024
Q4 		$15M Buy
779,998
+88,766
+13% +$1.93M 1.33% 18
2024
Q3 		$15.7M Buy
691,232
+123,745
+22% +$2.02M 1.08% 22
2024
Q2 		$7.38M Buy
567,487
+425,412
+299% +$5.89M 0.51% 34
2024
Q1 		$2.49M Buy
142,075
+4,732
+3% +$91.7K 0.17% 58
2023
Q4 		$2.99M Sell
137,343
-305,927
-69% -$4.83M 0.26% 44
2023
Q3 		$6.8M Buy
+443,270
New +$8.46M 0.58% 32
2022
Q4 		– Sell
-478,387
Closed -$9.81M – 81
2022
Q3 		$9.81M Buy
478,387
+32,795
+7% +$590K 0.85% 26
2022
Q2 		$5.16M Buy
445,592
+289,849
+186% +$3.9M 0.37% 47
2022
Q1 		$2.88M Sell
155,743
-38,846
-20% -$746K 0.22% 54
2021
Q4 		$3.85M Buy
194,589
+34,589
+22% +$644K 0.25% 66
2021
Q3 		$2.63M Buy
+160,000
New +$2.35M 0.18% 67

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Eversept Partners's VRDN Position: Q2 2026 in Review

Eversept Partners increased its Viridian Therapeutics (VRDN) stake by 17% in Q2 2026, buying an estimated $1.9M and bringing the position to 831,142 shares worth $15.3M. The position accounts for 0.79% of the portfolio, ranked #35.

Eversept Partners first reported a position in VRDN in Q3 2021 and has held it in 17 quarters since. The position peaked at $55.5M in Q4 2025. 214 funds tracked by Wall St. Rank hold VRDN as of Q2 2026.

  • Eversept Partners held 831,142 shares of Viridian Therapeutics worth $15.3M as of Q2 2026.
  • Eversept Partners bought 117,873 Viridian Therapeutics shares in Q2 2026, an estimated $1.9M.
  • Viridian Therapeutics made up 0.79% of Eversept Partners's portfolio in Q2 2026, its #35 holding.
  • Eversept Partners first reported a position in Viridian Therapeutics in Q3 2021 and has held it in 17 quarters since.
  • Eversept Partners's Viridian Therapeutics position peaked at $55.5M in Q4 2025.
  • 214 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q2 2026.

Based on Eversept Partners's 13F filing for Q2 2026, filed 14 Aug 2026.